Bielicki JA et al. (2016). Selecting appropriate empirical antibiotic regimens for paediatric bloodstream infections: application of a Bayesian decision model to local and pooled antimicrobial resistance surveillance data Journal of Antimicrobial Chemotherapy 71(3); doi:10.1093/jac/dkv397
Bielicki JA et al. (2020). Evaluation of the coverage of 3 antibiotic regimens for neonatal sepsis in the hospital setting across Asian countries JAMA Netw Open. 3(2):e1921124; doi:10.1001.jamanetworkopen.2019.21124
Bielicki JA et al. (2020). Evaluation of the coverage of 3 antibiotic regimens for neonatal sepsis in the hospital setting across Asian countries JAMA Netw Open. 3(2):e1921124; doi:10.1001/jamanetworkopen.2019.21124
Klinker KP et al. (2021). Antimicrobial stewardship and antibiograms: importance of moving beyond traditional antibiograms. Therapeutic Advances in Infectious Disease, May 5;8:20499361211011373; doi:10.1177/20499361211011373
Barbieri E et al. (2021). Development of a Weighted-Incidence Syndromic Combination Antibiogram (WISCA) to guide the choice of the empiric antibiotic treatment for urinary tract infection in paediatric patients: a Bayesian approach Antimicrobial Resistance & Infection Control May 1;10(1):74; doi:10.1186/s13756-021-00939-2
M39 Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data, 5th Edition, 2022, Clinical and Laboratory Standards Institute (CLSI). https://clsi.org/standards/products/microbiology/documents/m39/.
There are various antibiogram types, as summarised by Klinker et al. (2021, doi:10.1177/20499361211011373
), and they are all supported by antibiogram().
-For clinical coverage estimations, use WISCA whenever possible, since it provides more precise coverage estimates by accounting for pathogen incidence and antimicrobial susceptibility, as has been shown by Bielicki et al. (2020, doi:10.1001.jamanetworkopen.2019.21124
+
For clinical coverage estimations, use WISCA whenever possible, since it provides more precise coverage estimates by accounting for pathogen incidence and antimicrobial susceptibility, as has been shown by Bielicki et al. (2020, doi:10.1001/jamanetworkopen.2019.21124
). See the section Explaining WISCA on this page. Do note that WISCA is pathogen-agnostic, meaning that the outcome is not stratied by pathogen, but rather by syndrome.
Traditional Antibiogram
Case example: Susceptibility of Pseudomonas aeruginosa to piperacillin/tazobactam (TZP)
Code example:
diff --git a/reference/antimicrobial_selectors.html b/reference/antimicrobial_selectors.html
index d84ea4bea..bcc005ef1 100644
--- a/reference/antimicrobial_selectors.html
+++ b/reference/antimicrobial_selectors.html
@@ -17,7 +17,7 @@ my_data_with_all_these_columns %>%
AMR (for R)
- 2.1.1.9290
+ 3.0.0